Mr. Jones added, “Annexon is leading the development of first-in-kind upstream complement medicines with significant opportunities across neuroinflammatory diseases that have yet to be unlocked. I ...

NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Largest ever protein study set to revolutionise cancer and dementia tests - Tens of millions of pounds in investment is being provided by the group of firms which includes AstraZenecaa and Pfizer ...

A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today with ...

Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The research, which will begin in the UK this month, will aim to pinpoint how ...

Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

New treatments like dotinurad provide safer, more effective solutions for millions battling gout and hyperuricemia.

SAN DIEGO, CA / ACCESSWIRE / January 9, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...